Revisiting the Regenerative Therapeutic Advances Towards Erectile Dysfunction

Cells. 2020 May 19;9(5):1250. doi: 10.3390/cells9051250.

Abstract

Erectile dysfunction (ED) is an inability to attain or maintain adequate penile erection for successful vaginal intercourse, leading to sexual and relationship dissatisfaction. To combat ED, various surgical and non-surgical approaches have been developed in the past to restore erectile functions. These therapeutic interventions exhibit significant impact in providing relief to patients; however, due to their associated adverse effects and lack of long-term efficacy, newer modalities such as regenerative therapeutics have gained attention due to their safe and prolonged efficacy. Stem cells and platelet-derived biomaterials contained in platelet-rich plasma (PRP) are thriving as some of the major therapeutic regenerative agents. In recent years, various preclinical and clinical studies have evaluated the individual, as well as combined of stem cells and PRP to restore erectile function. Being rich in growth factors, chemokines, and angiogenic factors, both stem cells and PRP play a crucial role in regenerating nerve cells, myelination of axons, homing and migration of progenitor cells, and anti-fibrosis and anti-apoptosis of damaged cavernous nerve in corporal tissues. Further, platelet-derived biomaterials have been proven to be a biological supplement for enhancing the proliferative and differentiation potential of stem cells towards neurogenic fate. Therefore, this article comprehensively analyzes the progresses of these regenerative therapies for ED.

Keywords: erectile dysfunction (ED); intracavernosal injection; intracavernosal pressure (ICP); platelet-derived biomaterials; platelet-rich plasma (PRP); regenerative therapy; stem cells.

Publication types

  • Review

MeSH terms

  • Animals
  • Biocompatible Materials / therapeutic use
  • Cell- and Tissue-Based Therapy
  • Cell-Free System
  • Erectile Dysfunction / physiopathology
  • Erectile Dysfunction / therapy*
  • Humans
  • Male
  • Regenerative Medicine*
  • Treatment Outcome

Substances

  • Biocompatible Materials